Phototherapy for hyperbilirubinaemia in very low birthweight infants

MARTIN W. MONCRIEFF and JANET DUNN
From the Special Care Baby Unit, City Hospital, Derby

Moncrieff, M. W., and Dunn, J. (1976). Archives of Disease in Childhood, 51, 124. Phototherapy for hyperbilirubinaemia in very low birthweight infants. Phototherapy was used to treat 20 newborn babies whose birthweight was below 1500 g and whose plasma bilirubin level exceeded 8 mg/100 ml. The plasma bilirubin level was maintained below 13 mg/100 ml except in 4 babies whose level exceeded 13 mg/100 ml before treatment was started. In 60% of an untreated group of larger babies previously reported the plasma bilirubin level exceeded this figure.

Phototherapy seems to control the plasma bilirubin level satisfactorily in very low birthweight infants, but frequent measurements on the second and third days of life are advised in order that treatment may be started promptly when it exceeds 8 mg/100 ml.

Patients and methods
During the two years March 1973 to February 1975 42 babies weighing between 1000 g and 1499 g at birth were admitted to the Special Care Baby Unit in Derby (this was moved in March 1973 to new, well-lit, purpose-built accommodation). The total plasma bilirubin concentration in those babies who developed clinical jaundice was measured daily, or more often if indicated, by means of the AO reflectance meter. Babies whose plasma bilirubin exceeded 8 mg/100 ml were treated with continuous phototherapy until the level had fallen to below 8 mg/100 ml. Details of treatment, nursing care of the babies, and the precautions observed were the same as already described (Elliott et al., 1974). 17 of the babies died within 48 hours of birth and did not develop significant jaundice. In 20 of the remaining 25 babies the serum bilirubin concentration exceeded 8 mg/100 ml, and clinical details of these babies together with those of untreated, larger babies from our previous study are shown in Table I. One baby in this series received phenobarbitone, but no baby was given any drug known to potentiate jaundice and none had known blood group incompatibility. There was no untreated control group in the study.

TABLE I
Clinical details of 20 very low birthweight babies and of untreated, larger babies from previous study

<table>
<thead>
<tr>
<th></th>
<th>Very low birthweight (n = 20)</th>
<th>Untreated, larger babies (n = 45)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M/F)</td>
<td>14/6</td>
<td>27/18</td>
</tr>
<tr>
<td>Birthweight (g)</td>
<td>1390</td>
<td>2040</td>
</tr>
<tr>
<td>mean range</td>
<td>1170-1480</td>
<td></td>
</tr>
<tr>
<td>Gestation (w)</td>
<td>31.5</td>
<td>35.1</td>
</tr>
<tr>
<td>mean range</td>
<td>28-35</td>
<td></td>
</tr>
<tr>
<td>Severe asphyxia neonatorum</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Respiratory distress syndrome</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Severe bruising</td>
<td>None</td>
<td>4</td>
</tr>
</tbody>
</table>

Received 15 May 1975.
Since the plasma bilirubin rose more rapidly than expected in many babies treatment was started in only 4 babies at levels between 8 and 10 mg/100 ml, and in 4 it exceeded 13 mg/100 ml.

Results

The number of babies whose serum bilirubin level exceeded 10, 11, 12, 13, 14, and 15 mg/100 ml is shown in Table II together with the comparable number of untreated, larger babies already reported (Elliott et al., 1974). The mean and upper limit of the serum bilirubin level in the very low birthweight infants on each day of treatment are shown in the Fig. Phototherapy was required for a mean of 48 hours with a range of 1 to 5 days. In a few cases the serum bilirubin rose after treatment was stopped and a further period of phototherapy was given. 2 babies died on the fifth and sixth days of life from hyaline membrane disease. There was no evidence of kernicterus in these 2 babies either clinically or at post-mortem examination. No side effects of treatment were observed.

Discussion

We thought it was unethical to include a control group in whom treatment was delayed, but Table II shows that in 60% of untreated, larger babies the serum bilirubin exceeded 13 mg/100 ml. Our present study shows that phototherapy will nearly always prevent the plasma bilirubin exceeding this level, even in very small infants. Of the 4 babies whose level exceeded 13 mg/100 ml treatment was not started in 2 until the level was 14 mg/100 ml; the previous day it had been under 8 mg/100 ml in each case. In one baby the plasma bilirubin was 17 mg/100 ml when treatment was started because, unfortunately, it had not been measured the preceding day. It rose to 18 mg but later fell to 16 mg/100 ml on the day phototherapy was started. This baby was also given phenobarbitone. We intended to begin phototherapy when the plasma bilirubin exceeded 8 mg/100 ml, but owing to the rapid rise in the second and third days of life it actually exceeded 10 mg/100 ml in most cases before treatment was started. It might be safer to measure the plasma bilirubin at regular intervals as suggested by Tabb et al. (1972), twice a day on the second and third days of life, rather than rely on clinical judgement.

There is no absolutely safe level of plasma bilirubin in very small babies. Gartner et al. (1970) described 9 small infants who had evidence of kernicterus at post-mortem examination though the maximum serum bilirubin concentration was less than 13 mg/100 ml in 7. However, all were extremely ill with hyaline membrane disease and 7 weighed less than 1000 g at birth. Phototherapy failed to prevent kernicterus in 4 very small babies reported by Keenan et al. (1972), 2 of whom had a maximum serum bilirubin level of 10·5 mg/100 ml, but one of these 2 had meningitis and the other weighed only 454 g at birth. On the other hand, there was no evidence of kernicterus in the 2 babies in our series who died from hyaline membrane disease despite maximum plasma bilirubin levels of 14·5 and 12·5 mg/100 ml. Phototherapy has been used in Derby for the past 15 years. There has been no evidence of kernicterus in the survivors, even among those of very low birthweight.

Phototherapy by our method seems to prevent the plasma bilirubin exceeding 13 mg/100 ml in nearly all cases, and this seems to be a safe level except for extremely ill infants. We have not met any serious short-term side effects of phototherapy, and long-term complications seem very unlikely.

**TABLE II**

<table>
<thead>
<tr>
<th>Bilirubin (mg/100 ml)</th>
<th>% present series (n=20)</th>
<th>% previous serious (n=43)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 10</td>
<td>75 (15)</td>
<td>—</td>
</tr>
<tr>
<td>&gt; 11</td>
<td>55 (11)</td>
<td>—</td>
</tr>
<tr>
<td>&gt; 12</td>
<td>45 (9)</td>
<td>72 (31)</td>
</tr>
<tr>
<td>&gt; 13</td>
<td>20 (4)</td>
<td>60 (26)</td>
</tr>
<tr>
<td>&gt; 14</td>
<td>10 (2)</td>
<td>49 (22)</td>
</tr>
<tr>
<td>&gt; 15</td>
<td>5 (1)</td>
<td>44 (19)</td>
</tr>
</tbody>
</table>

FIG.—Mean and maximum plasma bilirubin levels in very low birthweight infants treated with phototherapy.
Moncrieff and Dunn

(Lucey, 1971). Nevertheless, we are following up our previous series carefully with this in mind.

We thank Dr. B. S. B. Wood for advice in the preparation of this paper.

REFERENCES


Correspondence to Dr. M. W. Moncrieff, Radcliffe Infirmary, Oxford.
Phototherapy for hyperbilirubinaemia in very low birthweight infants.
M W Moncrieff and J Dunn

Arch Dis Child 1976 51: 124-126
doi: 10.1136/adc.51.2.124

Updated information and services can be found at:
http://adc.bmj.com/content/51/2/124

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/